ANALYSIS: US FDA boost narrows gap for ReShape in obesity balloon race
This article was originally published in Clinica
ReShape Medical has received a boost after the US FDA reportedly said it would not need to go through an advisory panel meeting for its ReShape Duo obesity balloon. ReShape submitted a premarket approval application to the agency in July 2014; it is designed to help weight loss in patients with a body mass index of 30-40.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.